Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
- PMID: 15937495
- DOI: 10.1038/nm1258
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
Abstract
Vaccines and therapies are urgently needed to address public health needs stemming from emerging pathogens and biological threat agents such as the filoviruses Ebola virus (EBOV) and Marburg virus (MARV). Here, we developed replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors expressing either the EBOV glycoprotein or MARV glycoprotein. A single intramuscular injection of the EBOV or MARV vaccine elicited completely protective immune responses in nonhuman primates against lethal EBOV or MARV challenges. Notably, vaccine vector shedding was not detectable in the monkeys and none of the animals developed fever or other symptoms of illness associated with vaccination. The EBOV vaccine induced humoral and apparent cellular immune responses in all vaccinated monkeys, whereas the MARV vaccine induced a stronger humoral than cellular immune response. No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model.
Comment in
-
A single shot against Ebola and Marburg virus.Nat Med. 2005 Jul;11(7):720-1. doi: 10.1038/nm0705-720. Nat Med. 2005. PMID: 16015361 No abstract available.
Similar articles
-
A single shot against Ebola and Marburg virus.Nat Med. 2005 Jul;11(7):720-1. doi: 10.1038/nm0705-720. Nat Med. 2005. PMID: 16015361 No abstract available.
-
Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections.Vaccine. 2005 Apr 27;23(23):3033-42. doi: 10.1016/j.vaccine.2004.11.070. Vaccine. 2005. PMID: 15811650
-
Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection.Vaccine. 2004 Sep 3;22(25-26):3495-502. doi: 10.1016/j.vaccine.2004.01.063. Vaccine. 2004. PMID: 15308377
-
Development of vaccines for Marburg hemorrhagic fever.Expert Rev Vaccines. 2007 Feb;6(1):57-74. doi: 10.1586/14760584.6.1.57. Expert Rev Vaccines. 2007. PMID: 17280479 Review.
-
Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses.Virus Res. 2011 Dec;162(1-2):148-61. doi: 10.1016/j.virusres.2011.09.005. Epub 2011 Sep 10. Virus Res. 2011. PMID: 21925552 Review.
Cited by
-
Understanding Viral Haemorrhagic Fevers: Virus Diversity, Vector Ecology, and Public Health Strategies.Pathogens. 2024 Oct 18;13(10):909. doi: 10.3390/pathogens13100909. Pathogens. 2024. PMID: 39452780 Free PMC article. Review.
-
Filovirus vaccines as a response paradigm for emerging infectious diseases.NPJ Vaccines. 2024 Oct 11;9(1):186. doi: 10.1038/s41541-024-00985-y. NPJ Vaccines. 2024. PMID: 39394249 Free PMC article. Review.
-
Structural Heterogeneity of the Rabies Virus Virion.Viruses. 2024 Sep 11;16(9):1447. doi: 10.3390/v16091447. Viruses. 2024. PMID: 39339924 Free PMC article.
-
Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design.Nat Commun. 2024 Sep 17;15(1):8133. doi: 10.1038/s41467-024-51021-5. Nat Commun. 2024. PMID: 39285186 Free PMC article.
-
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.Signal Transduct Target Ther. 2024 Sep 11;9(1):223. doi: 10.1038/s41392-024-01917-x. Signal Transduct Target Ther. 2024. PMID: 39256346 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
